Does Losartan reduce the severity of COVID-19 in hypertensive patients?

{ 'indexed': {'date-parts': [[2023, 9, 1]], 'date-time': '2023-09-01T10:24:29Z', 'timestamp': 1693563869569}, 'reference-count': 29, 'publisher': 'Springer Science and Business Media LLC', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2022, 3, 19]], 'date-time': '2022-03-19T00:00:00Z', 'timestamp': 1647648000000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}, { 'start': { 'date-parts': [[2022, 3, 19]], 'date-time': '2022-03-19T00:00:00Z', 'timestamp': 1647648000000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}], 'funder': [{'name': 'Yazd University of Medical Sciences', 'award': ['7867', '7867', '7867', '7867']}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2022, 12]]}, 'abstract': '<jats:title>Abstract</jats:title><jats:sec>\n' ' <jats:title>Background</jats:title>\n' ' <jats:p>One of the global problems is to control the coronavirus epidemic, ' 'and the role of different medicines is still unknown to policymakers. This study was ' 'conducted to evaluate the effects of losartan on the mortality rate of COVID-19 in ' 'hypertensive patients.</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Methods</jats:title>\n' ' <jats:p>The research sample of analytical study included 1458 patients ' 'presenting to COVID-19 diagnostic centers in Yazd that were examined in the first six months ' 'of 2020. Data were analyzed using descriptive statistics as well as chi-square, Fisher’s ' 'exact test, <jats:italic>t</jats:italic> test, and logistic regression.</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Results</jats:title>\n' ' <jats:p>Of 1458 subjects that were studied, 280 were hypertensive of whom 179 ' 'tested positive for SARS-CoV-2 PCR. The results showed a lower chance of death by more than 5 ' 'times in hypertensive patients who used losartan (<jats:italic>P</jats:italic> = 0.003).\xa0' 'Moreover, regarding the effect of losartan on the prevention of COVID-19 in hypertensive ' 'patients, it was found that this medicine played a protective role although this relationship ' 'was not statistically significant (<jats:italic>P</jats:italic> = 0.86).</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Conclusions</jats:title>\n' ' <jats:p>The results showed that losartan reduced the chance of mortality in ' 'hypertensive patients. It is recommended that the effect of losartan and other blood pressure ' 'medicines on COVID-19 patients be investigated in larger studies as well as laboratory ' 'investigations.</jats:p>\n' ' </jats:sec>', 'DOI': '10.1186/s12872-022-02548-2', 'type': 'journal-article', 'created': {'date-parts': [[2022, 3, 19]], 'date-time': '2022-03-19T12:03:22Z', 'timestamp': 1647691402000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 3, 'title': 'Does Losartan reduce the severity of COVID-19 in hypertensive patients?', 'prefix': '10.1186', 'volume': '22', 'author': [ {'given': 'Mohammadreza', 'family': 'Mirjalili', 'sequence': 'first', 'affiliation': []}, {'given': 'Moslem Taheri', 'family': 'Soodejani', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mehdi', 'family': 'Raadabadi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ali', 'family': 'Dehghani', 'sequence': 'additional', 'affiliation': []}, {'given': 'Fateme', 'family': 'Salemi', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2022, 3, 19]]}, 'reference': [ { 'issue': '2', 'key': '2548_CR1', 'doi-asserted-by': 'publisher', 'first-page': '135', 'DOI': '10.3390/v12020135', 'volume': '12', 'author': 'LE Gralinski', 'year': '2020', 'unstructured': 'Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. ' 'Viruses. 2020;12(2):135. https://doi.org/10.3390/v12020135.', 'journal-title': 'Viruses'}, { 'issue': '1', 'key': '2548_CR2', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.12659/msm.925364', 'volume': '8', 'author': 'MS Alshahrani', 'year': '2018', 'unstructured': 'Alshahrani MS, Sindi A, Alshamsi F, Al-Omari A, El Tahan M, Alahmadi B, ' 'et al. Extracorporeal membrane oxygenation for severe Middle East ' 'respiratory syndrome coronavirus. Ann Intensive Care. 2018;8(1):1–10. ' 'https://doi.org/10.12659/msm.925364.', 'journal-title': 'Ann Intensive Care'}, { 'issue': '10229', 'key': '2548_CR3', 'doi-asserted-by': 'publisher', 'first-page': '1054', 'DOI': '10.1016/S0140-6736(20)30566-3', 'volume': '395', 'author': 'F Zhou', 'year': '2020', 'unstructured': 'Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk ' 'factors for mortality of adult inpatients with COVID-19 in Wuhan, China: ' 'a retrospective cohort study. Lancet. 2020;395(10229):1054–62. ' 'https://doi.org/10.1016/S0140-6736(20)30566-3.', 'journal-title': 'Lancet'}, { 'issue': '7', 'key': '2548_CR4', 'doi-asserted-by': 'publisher', 'first-page': '1382', 'DOI': '10.2337/dc20-0598', 'volume': '43', 'author': 'Q Shi', 'year': '2020', 'unstructured': 'Shi Q, Zhang X, Jiang F, Zhang X, Hu N, Bimu C, et al. Clinical ' 'characteristics and risk factors for mortality of COVID-19 patients with ' 'diabetes in Wuhan, China: a two-center, retrospective study. Diabetes ' 'care. 2020;43(7):1382–91. https://doi.org/10.2337/dc20-0598.', 'journal-title': 'Diabetes care'}, { 'issue': '6', 'key': '2548_CR5', 'doi-asserted-by': 'publisher', 'first-page': 'e14-e8', 'DOI': '10.1016/j.jinf.2020.03.005', 'volume': '80', 'author': 'K Liu', 'year': '2020', 'unstructured': 'Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly ' 'patients: a comparison with young and middle-aged patients. J Infection. ' '2020;80(6):e14–8. https://doi.org/10.1016/j.jinf.2020.03.005.', 'journal-title': 'J Infection'}, { 'issue': '13', 'key': '2548_CR6', 'doi-asserted-by': 'publisher', 'first-page': '1239', 'DOI': '10.1001/jama.2020.2648', 'volume': '323', 'author': 'Z Wu', 'year': '2020', 'unstructured': 'Wu Z, McGoogan JM. Characteristics of and important lessons from the ' 'coronavirus disease 2019 (COVID-19) outbreak in China: summary of a ' 'report of 72 314 cases from the Chinese Center for Disease Control and ' 'Prevention. Jama. 2020;323(13):1239–42. ' 'https://doi.org/10.1001/jama.2020.2648.', 'journal-title': 'Jama'}, { 'key': '2548_CR7', 'doi-asserted-by': 'publisher', 'unstructured': 'Puskarich MA, Ingraham NE, Merck LH, Driver BE, Wacker DA, Black LP, et ' 'al. Effect of losartan on hospitalized patients with COVID-19-induced ' 'lung injury: A randomized clinical trial. medRxiv. 2021. ' 'https://doi.org/10.1101/2021.08.25.21262623.', 'DOI': '10.1101/2021.08.25.21262623'}, { 'issue': '1', 'key': '2548_CR8', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1007/s40203-020-00058-7', 'volume': '9', 'author': 'R Nejat', 'year': '2021', 'unstructured': 'Nejat R, Sadr AS. Are losartan and imatinib effective against SARS-CoV2 ' 'pathogenesis? A pathophysiologic-based in silico study. In silico ' 'Pharmacol. 2021;9(1):1–22. https://doi.org/10.1007/s40203-020-00058-7.', 'journal-title': 'In silico Pharmacol'}, { 'key': '2548_CR9', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1186/s13063-017-2427-0', 'volume': '19', 'author': 'YM Arabi', 'year': '2018', 'unstructured': 'Arabi YM, Alothman A, Balkhy HH, Al-Dawood A, AlJohani S, Al Harbi S, et ' 'al. Treatment of Middle East respiratory syndrome with a combination of ' 'lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol ' 'for a randomized controlled trial. Trials. 2018;19:1–13. ' 'https://doi.org/10.1186/s13063-017-2427-0.', 'journal-title': 'Trials.'}, { 'key': '2548_CR10', 'doi-asserted-by': 'crossref', 'unstructured': 'Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L. ' 'Dexamethasone in Hospitalized Patients with Covid-19. ' '2021;384(8):693–704. https://dx.doi.org/10.1056%2FNEJMoa2021436.', 'DOI': '10.1056/NEJMoa2021436'}, { 'issue': '21', 'key': '2548_CR11', 'doi-asserted-by': 'publisher', 'first-page': '4813', 'DOI': '10.1111/bph.15072', 'volume': '177', 'author': 'C Scavone', 'year': '2020', 'unstructured': 'Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli A, ' 'et al. Current pharmacological treatments for COVID-19: What’s next? Br ' 'J Pharmacol. 2020;177(21):4813–24. https://doi.org/10.1111/bph.15072.', 'journal-title': 'Br J Pharmacol'}, { 'key': '2548_CR12', 'doi-asserted-by': 'publisher', 'DOI': '10.20944/preprints202003.0457.v1', 'author': 'AS Jazzi', 'year': '2020', 'unstructured': 'Jazzi AS, Mahnam K, Hejazi SH, Damavandi MS, Sadeghi P, Zeinalian M, et ' 'al. Inhibition of viral macrodomain of covid-19 and human trpm2 by ' 'losartan. Preprint. 2020. ' 'https://doi.org/10.20944/preprints202003.0457.v1.', 'journal-title': 'Preprint'}, { 'issue': '6', 'key': '2548_CR13', 'doi-asserted-by': 'publisher', 'first-page': '752', 'DOI': '10.1017/ice.2020.80', 'volume': '41', 'author': 'M Zeinalian', 'year': '2020', 'unstructured': 'Zeinalian M, Salari-Jazi A, Jannesari A, Khanahmad H. A potential ' 'protective role of losartan against coronavirus-induced lung damage. ' 'Infection Control Hosp Epidemiol. 2020;41(6):752–3. ' 'https://doi.org/10.1017/ice.2020.80.', 'journal-title': 'Infection Control Hosp Epidemiol'}, { 'issue': '19', 'key': '2548_CR14', 'doi-asserted-by': 'publisher', 'first-page': '1519', 'DOI': '10.1136/heartjnl-2020-317336', 'volume': '106', 'author': 'ME Flacco', 'year': '2020', 'unstructured': 'Flacco ME, Martellucci CA, Bravi F, Parruti G, Cappadona R, Mascitelli ' 'A, et al. Treatment with ACE inhibitors or ARBs and risk of ' 'severe/lethal COVID-19: a meta-analysis. Heart. 2020;106(19):1519–24. ' 'https://doi.org/10.1136/heartjnl-2020-317336.', 'journal-title': 'Heart'}, { 'issue': '2', 'key': '2548_CR15', 'doi-asserted-by': 'publisher', 'first-page': '145', 'DOI': '10.2217/fvl.10.4', 'volume': '5', 'author': 'BA Wevers', 'year': '2010', 'unstructured': 'Wevers BA. Hoek Lvd. Renin–angiotensin system in human coronavirus ' 'pathogenesis. Future Virol. 2010;5(2):145–61. ' 'https://doi.org/10.2217/fvl.10.4.', 'journal-title': 'Future Virol'}, { 'key': '2548_CR16', 'doi-asserted-by': 'publisher', 'unstructured': 'Clarke NE, Turner AJ. Angiotensin-converting enzyme 2: the first decade. ' 'Int J Hypertens. 2012;2012. https://doi.org/10.1155/2012/307315.', 'DOI': '10.1155/2012/307315'}, { 'issue': '2', 'key': '2548_CR17', 'doi-asserted-by': 'publisher', 'first-page': '181', 'DOI': '10.1016/S0163-7258(97)82002-5', 'volume': '74', 'author': 'M McIntyre', 'year': '1997', 'unstructured': 'McIntyre M, Caffe S, Michalak R, Reid J. Losartan, an orally active ' 'angiotensin (AT1) receptor antagonist: a review of its efficacy and ' 'safety in essential hypertension. Pharmacol Therap. 1997;74(2):181–94. ' 'https://doi.org/10.1016/S0163-7258(97)82002-5.', 'journal-title': 'Pharmacol Therap'}, { 'issue': '3', 'key': '2548_CR18', 'doi-asserted-by': 'publisher', 'first-page': '249', 'DOI': '10.21037/hbsn.2016.02.06', 'volume': '5', 'author': 'ZA Salama', 'year': '2016', 'unstructured': 'Salama ZA, Sadek A, Abdelhady AM, Darweesh SK, Morsy SA, Esmat G. ' 'Losartan may inhibit the progression of liver fibrosis in chronic HCV ' 'patients. Hepatob Surg Nutr. 2016;5(3):249.', 'journal-title': 'Hepatob Surg Nutr'}, { 'issue': '3', 'key': '2548_CR19', 'doi-asserted-by': 'publisher', 'first-page': '574', 'DOI': '10.1016/j.ajpath.2017.11.006', 'volume': '188', 'author': 'SL Sellers', 'year': '2018', 'unstructured': 'Sellers SL, Milad N, Chan R, Mielnik M, Jermilova U, Huang PL, et al. ' 'Inhibition of Marfan Syndrome Aortic Root Dilation by Losartan: Role of ' 'Angiotensin II Receptor Type 1–Independent Activation of Endothelial ' 'Function. Am J Pathol. 2018;188(3):574–85. ' 'https://doi.org/10.1016/j.ajpath.2017.11.006.', 'journal-title': 'Am J Pathol'}, { 'issue': '6', 'key': '2548_CR20', 'doi-asserted-by': 'publisher', 'first-page': 'e0218471', 'DOI': '10.1371/journal.pone.0218471', 'volume': '14', 'author': 'JA Choi', 'year': '2019', 'unstructured': 'Choi JA, Kim J-E, Ju H-h, Lee J, Jee D, Park CK, et al. The effects of ' 'losartan on cytomegalovirus infection in human trabecular meshwork ' 'cells. Plos one. 2019;14(6):e0218471. ' 'https://doi.org/10.1371/journal.pone.0218471.', 'journal-title': 'Plos one'}, { 'issue': '5', 'key': '2548_CR21', 'doi-asserted-by': 'publisher', 'first-page': '730', 'DOI': '10.1002/cbic.202000047', 'volume': '21', 'author': 'JS Morse', 'year': '2020', 'unstructured': 'Morse JS, Lalonde T, Xu S, Liu WR. Learning from the past: possible ' 'urgent prevention and treatment options for severe acute respiratory ' 'infections caused by 2019-nCoV. Chembiochem. 2020;21(5):730. ' 'https://dx.doi.org/10.1002%2Fcbic.202000047.', 'journal-title': 'Chembiochem'}, { 'issue': '5', 'key': '2548_CR22', 'doi-asserted-by': 'publisher', 'first-page': 'e96353', 'DOI': '10.1371/journal.pone.0096353', 'volume': '9', 'author': 'M Ivanov', 'year': '2014', 'unstructured': 'Ivanov M, Mihailović-Stanojević N, Grujić Milanović J, Jovović Đ, ' 'Marković-Lipkovski J, Ćirović S, et al. Losartan improved antioxidant ' 'defense, renal function and structure of postischemic hypertensive ' 'kidney. PloS one. 2014;9(5):e96353. ' 'https://doi.org/10.1371/journal.pone.0096353.', 'journal-title': 'PloS one'}, { 'key': '2548_CR23', 'doi-asserted-by': 'publisher', 'unstructured': 'Kouhpayeh S, Shariati L, Boshtam M, Rahimmanesh I, Mirian M, Zeinalian ' 'M, et al. The molecular story of COVID-19; NAD+ depletion addresses all ' 'questions in this infection. 2020. Kouhpayeh, S.; Shariati, L.; Boshtam, ' 'M.; Rahimmanesh, I.; Mirian, M.; Zeinalian, M.; Salari-jazi, A.; ' 'Khanahmad, N.; Damavandi, M.S.; Sadeghi, P.; Khanahmad, H. The Molecular ' 'Story of COVID-19; NAD+ Depletion Addresses All Questions in this ' 'Infection. Preprints 2020, 2020030346 ' 'https://doi.org/10.20944/preprints202003.0346.v1.', 'DOI': '10.20944/preprints202003.0346.v1'}, { 'key': '2548_CR24', 'doi-asserted-by': 'crossref', 'unstructured': 'Covid C, Team R, COVID C, Team R, COVID C, Team R, et al. Severe ' 'outcomes among patients with coronavirus disease 2019 (COVID-19)—United ' 'States, February 12–March 16, 2020. Morbidity and mortality weekly ' 'report. 2020;69(12):343. https://dx.doi.org/10.15585%2Fmmwr.mm6912e2.', 'DOI': '10.15585/mmwr.mm6912e2'}, { 'key': '2548_CR25', 'unstructured': 'TNCPERE T. Vital surveillances: the epidemiological characteristics of ' 'an outbreak of 2019 novel coronavirus disease (COVID-19)-China, 2020. ' '2020.'}, { 'issue': '6', 'key': '2548_CR26', 'doi-asserted-by': 'publisher', 'first-page': '767', 'DOI': '10.1016/j.cmi.2020.04.012', 'volume': '26', 'author': 'J Zhang', 'year': '2020', 'unstructured': 'Zhang J, Wang X, Jia X, Li J, Hu K, Chen G, et al. Risk factors for ' 'disease severity, unimprovement, and mortality in COVID-19 patients in ' 'Wuhan, China. Clin Microbiol Infect. 2020;26(6):767–72. ' 'https://doi.org/10.1016/j.cmi.2020.04.012.', 'journal-title': 'Clin Microbiol Infect'}, { 'issue': '7', 'key': '2548_CR27', 'doi-asserted-by': 'publisher', 'first-page': '811', 'DOI': '10.1001/jamacardio.2020.1017', 'volume': '5', 'author': 'T Guo', 'year': '2020', 'unstructured': 'Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular ' 'implications of fatal outcomes of patients with coronavirus disease 2019 ' '(COVID-19). JAMA Cardiol. 2020;5(7):811–8. ' 'https://doi.org/10.1001/jamacardio.2020.1017.', 'journal-title': 'JAMA Cardiol'}, { 'issue': '5', 'key': '2548_CR28', 'doi-asserted-by': 'publisher', 'first-page': '3504', 'DOI': '10.1002/ehf2.13462', 'volume': '8', 'author': 'V Nuzzi', 'year': '2021', 'unstructured': 'Nuzzi V, Merlo M, Specchia C, Lombardi CM, Carubelli V, Iorio A, et al. ' 'The prognostic value of serial troponin measurements in patients ' 'admitted for COVID-19. ESC Heart Failure. 2021;8(5):3504–11. ' 'https://doi.org/10.1002/ehf2.13462.', 'journal-title': 'ESC Heart Failure'}, { 'issue': '1', 'key': '2548_CR29', 'doi-asserted-by': 'publisher', 'first-page': '757', 'DOI': '10.1080/22221751.2020.1746200', 'volume': '9', 'author': 'J Meng', 'year': '2020', 'unstructured': 'Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, et al. Renin-angiotensin ' 'system inhibitors improve the clinical outcomes of COVID-19 patients ' 'with hypertension. Emerg Microb Infect. 2020;9(1):757–60. ' 'https://doi.org/10.1080/22221751.2020.1746200.', 'journal-title': 'Emerg Microb Infect'}], 'container-title': 'BMC Cardiovascular Disorders', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1186/s12872-022-02548-2.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1186/s12872-022-02548-2/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1186/s12872-022-02548-2.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 3, 19]], 'date-time': '2022-03-19T12:09:27Z', 'timestamp': 1647691767000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-022-02548-2'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 3, 19]]}, 'references-count': 29, 'journal-issue': {'issue': '1', 'published-print': {'date-parts': [[2022, 12]]}}, 'alternative-id': ['2548'], 'URL': 'http://dx.doi.org/10.1186/s12872-022-02548-2', 'relation': {}, 'ISSN': ['1471-2261'], 'subject': [], 'container-title-short': 'BMC Cardiovasc Disord', 'published': {'date-parts': [[2022, 3, 19]]}, 'assertion': [ { 'value': '22 August 2021', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '8 March 2022', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '19 March 2022', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, {'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Declarations'}}, { 'value': 'The article’s proposal was approved by the ethics committee of Shahid Sadoughi ' 'University of Medical Sciences with the ID of IR.SSU.REC.1399.101. Due to the ' 'retrospective nature of the study, no study specific consent form was used. ' 'However, patients admitted to our hospital are asked to sign a general consent ' 'upon admission, which covers the collection of patient data and publication of ' 'these results. Therefore, the individual’s informed consent was waived by the ' 'above ethics committee. We received administrative permission from (Secretary ' 'of University/Regional Research Ethics Committee Shahid Sadoughi University of ' 'Medical Sciences) to access and use the data. Data used in the study were ' 'anonymized. The ethics committee approved this procedure with the above ' 'ethical code. The present study was conducted in terms of the principles of ' 'the revised Declaration of Helsinki, which waived requirement for informed ' 'consent.', 'order': 2, 'name': 'Ethics', 'group': { 'name': 'EthicsHeading', 'label': "<!--Emphasis Type='Bold' removed-->Ethics approval and consent to " 'participate'}}, { 'value': 'Not applicable.', 'order': 3, 'name': 'Ethics', 'group': { 'name': 'EthicsHeading', 'label': "<!--Emphasis Type='Bold' removed-->Consent for publication"}}, { 'value': 'All authors declare that they have no conflict of interest regarding this ' 'study.', 'order': 4, 'name': 'Ethics', 'group': { 'name': 'EthicsHeading', 'label': "<!--Emphasis Type='Bold' removed-->Competing interests"}}], 'article-number': '116'}